![]() |
市场调查报告书
商品编码
1884058
可吸收缝合线市场规模、占有率、成长及全球产业分析:依类型、应用和地区划分的洞察与预测(2024-2032)Absorbable Sutures Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032 |
||||||
2024年全球可吸收缝线市场规模为36亿美元,预计2025年将成长至37.9亿美元,到2032年将达到64.4亿美元。北美地区在2024年占市场主导地位,市场占有率为41.11%,这得益于其先进的医疗基础设施和较高的手术量。可吸收缝合线(也称为溶解缝合线或可吸收缝合线)旨在随着时间的推移在体内自然降解,无需取出,因此非常适合用于体内手术。这些缝合线由天然材料(例如羊肠线)或合成聚合物(例如聚二氧杂环己酮、聚乳酸-羟基乙酸共聚物和聚己内酯)製成。
市场动态:市场推动因素、阻碍因素与机会
全球外科手术数量的不断增长是可吸收缝合线市场的主要推动因素。在美国,每年约进行130万例膝关节置换术及76万例髋关节置换术。全球每年约进行40万例冠状动脉绕道手术(CABG)。此外,人口老化导致血管成形术、关节置换术和器官移植等手术的需求日益增长,增加了对缝合线的需求。现代缝合器械的高效性也促进了其广泛应用,并推动了市场成长。
然而,人们越来越倾向于使用其他伤口闭合方法,例如手术钉、组织黏合剂和止血剂,这在一定程度上限制了市场成长。在开放手术和骨科手术中,缝合钉被广泛用于快速缝合伤口;而在美容和皮肤外科手术中,为了最大限度地减少疤痕,人们更倾向于使用黏合剂。这些替代方法尤其在急诊手术中被优先考虑,这往往限制了可吸收缝线的应用。
缝合技术的创新正在推动市场机会。合成聚合物(例如聚乙醇酸-共-L-乳酸)(PGA-L)和二乙酰几丁质,以及抗菌涂层(例如三氯生)的进步,提高了缝合线的抗拉强度、生物相容性和吸收性能。二乙酰几丁质衍生缝合线的研究表明,其在14天时强度保持率为63%,在42天时完全吸收,并且组织修復速度更快,与传统缝合线相比,可带来更好的手术效果。
新兴趋势
无结可吸收缝线在微创手术(如骨科、心血管和腹腔镜手术)中备受关注。这些缝合线可降低感染风险,无需拆线,并能实现一致的伤口闭合,避免了打结带来的挑战。研究表明,与传统缝线相比,可吸收无结倒刺缝线在术后 60 天和 90 天可显着降低手术部位感染率。合成生物工程缝线和抗菌涂层缝线等技术进步,以及机器人辅助手术的出现,正在进一步加速其应用。
依类型划分,多股/编织缝合线因其在心臟和假体手术中卓越的操控性、结节安全性和灵活性,预计将在 2024 年占市场主导地位。单丝缝合线在血管和显微血管外科手术中也占了相当大的市场占有率,这主要得益于其较低的感染风险。
以缝合方式划分,由于合成缝线可降低过敏反应的风险,预计在2024年,合成缝线将占市场主导地位。同时,由于天然缝合线(例如羊肠线)具有高吸收性和成本效益,因此在眼科、妇科和整形外科手术中更受欢迎。
依应用领域划分,骨科领域将在2024年引领市场,2023年美洲地区共进行了370万例关节置换手术。妇产科也将占较大占有率,这主要得益于剖腹产率的上升(预计将从2020年的21%上升到2030年的29%)。心臟手术(包括儿科和先天性心臟病手术)占第二大市场占有率,在美国每年进行超过 4 万例手术。其他应用,例如普通外科手术、整形外科手术和眼科手术,也推动了整体市场成长。
依最终用户划分,由于手术量大且报销制度有利,医院和门诊手术中心 (ASC) 预计在 2024 年将占市场主导地位。专科诊所和其他机构,包括教学医院和军事医院,也为市场成长做出了贡献。
预计到 2024 年,北美将以 14.8 亿美元的市占率引领市场。欧洲将占第二大市场占有率,这主要得益于骨科手术量大。亚太地区预计将实现最快成长,这主要得益于 Healthium Medtech 的 TRUMAS 缝线等新产品的推出。整形手术将推动拉丁美洲的成长,而中东和非洲的成长将较为温和,这主要是由于慢性病的增加。
The global absorbable sutures market was valued at USD 3.60 billion in 2024, and it is projected to grow to USD 3.79 billion in 2025, reaching USD 6.44 billion by 2032. North America dominated the market in 2024, holding a 41.11% share, driven by advanced healthcare infrastructure and high surgical volumes. Absorbable sutures, also known as dissolvable or resorbable sutures, are designed to naturally degrade in the body over time, eliminating the need for removal and making them ideal for internal surgical applications. These sutures are manufactured from natural materials such as catgut and synthetic polymers, including polydioxanone, polyglactin, and poliglecaprone.
Market Dynamics: Drivers, Restraints, and Opportunities
The rising number of surgeries globally is a major driver for absorbable sutures. In the U.S., approximately 1.3 million knee replacements and 760,000 hip replacements are performed annually. Worldwide, around 400,000 coronary artery bypass graft (CABG) surgeries are conducted each year. Moreover, the aging population requires frequent procedures such as angioplasty, joint replacements, and organ transplants, increasing suture demand. The high efficiency of modern suturing devices also contributes to broader adoption, fueling market growth.
However, the growing preference for alternative wound closure methods, such as surgical staples, tissue adhesives, and hemostats, restrains market growth. Staples, commonly used in laparotomy and orthopedic surgeries, offer rapid closure, while adhesives are favored in cosmetic and dermatological procedures to minimize scarring. These alternatives are particularly preferred in emergency interventions, limiting the adoption of absorbable sutures.
Market opportunities are driven by innovations in suture technology. Advancements in synthetic polymers, such as poly(glycolide-co-l-lactide) (PGA-L) and diacetyl chitin, along with antimicrobial coatings like Triclosan, have enhanced tensile strength, biocompatibility, and absorption profiles. Research on diacetyl chitin-derived sutures demonstrated 63% strength retention at 14 days, full absorption by 42 days, and faster tissue repair, providing improved outcomes compared to traditional sutures.
Emerging Trends
Knotless absorbable sutures are gaining traction, especially in minimally invasive surgeries such as orthopedic, cardiovascular, and laparoscopic procedures. These sutures reduce infection risk, eliminate the need for removal, and provide consistent wound closure without knot-tying challenges. Studies indicate that absorbable knotless barbed sutures significantly reduce surgical site infections at 60 and 90 days post-operation compared to conventional sutures. Technological advancements, including synthetic bioengineered and antimicrobial-coated sutures, coupled with robotic-assisted surgeries, further accelerate adoption.
By type, multifilament/braided sutures dominated in 2024 due to superior handling, knot security, and flexibility in cardiac and prosthetic surgeries. Monofilament sutures also held a substantial share, preferred in vascular and microvascular procedures due to lower infection risk.
By form, synthetic sutures dominated in 2024 due to reduced hypersensitivity reactions, while natural sutures like catgut were preferred in ophthalmic, gynecological, and plastic surgeries because of higher absorbability and cost-effectiveness.
By application, orthopedics led the market in 2024, with 3.7 million arthroplasty procedures performed in the Americas in 2023. Gynecology accounted for a significant share, supported by rising cesarean section rates, projected to increase from 21% in 2020 to 29% by 2030. Cardiology, including pediatric and congenital heart surgeries, accounted for the second-largest share, with over 40,000 surgeries performed annually in the U.S. General surgery and other applications, such as cosmetic and ophthalmic surgeries, contributed to overall market growth.
By end-user, hospitals and ambulatory surgical centers (ASCs) dominated the market in 2024 due to higher surgical volumes and favorable reimbursement. Specialty clinics and other facilities, including academic and military hospitals, also contributed to growth.
North America led the market with USD 1.48 billion in 2024. Europe held the second-largest share, driven by high orthopedic surgery volumes, while Asia Pacific is expected to grow the fastest, fueled by new product launches such as Healthium Medtech's TRUMAS sutures. Latin America's growth is driven by cosmetic procedures, while the Middle East & Africa shows moderate growth due to increasing prevalence of chronic diseases.
Competitive Landscape
Key players include Johnson & Johnson Services, Medtronic, B. Braun SE, Genesis Medtech, and Dolphin Sutures. Strategies focus on regulatory approvals, new product launches, and partnerships. Notable developments include Genesis MedTech receiving NMPA approval in China for antibacterial sutures (2023) and Orion Sutures' participation in MEDICA 2024 in Germany.
Conclusion
The absorbable sutures market, valued at USD 3.60 billion in 2024 and expected to reach USD 6.44 billion by 2032, is experiencing robust growth due to increasing surgical demand, technological innovation, and rising adoption of knotless and synthetic sutures. While alternatives like staples and adhesives pose challenges, advancements and regional expansions present significant opportunities for market players globally.
Segmentation By Type
By Form
By Application
By End-user
By Region